Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regen BioPharmaRGBP Days Sales Outstanding is 423.00 as of Jun. 2026, which is 47% above its 10-year median of 288.68. The stock has 8 warning signs investors should review. Among 835 Biotechnology companies, Regen BioPharma ranks worse than 93.53% on this metric.
Regen BioPharma (OTCPK:RGBP) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Regen BioPharma Days Sales Outstanding Related Terms
Regen BioPharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs IOBTQ, SCPX, LIPO: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Regen BioPharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Days Sales Outstanding falls into.
Regen BioPharma Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 423.00 mean?
Regen BioPharma (RGBP) has a Days Sales Outstanding of 423.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Regen BioPharma and its competitors. This is 47% above median its historical median of 288.68. Over the past decade, Regen BioPharma's Days Sales Outstanding has ranged from 146.31 to 391.18. According to the industry distribution chart, Regen BioPharma ranks #781 out of 835 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Regen BioPharma's Days Sales Outstanding too high?
Regen BioPharma's current Days Sales Outstanding of 423.00 is 47% above median its 10-year median of 288.68. Over the past 10 years, this metric has ranged from a low of 146.31 to a high of 391.18. The Biotechnology industry median Days Sales Outstanding is 68.94. Regen BioPharma's value of 423.00 is 513.6% above this industry median. Based on the distribution chart, Regen BioPharma ranks #781 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's Days Sales Outstanding compare to IOBTQ and SCPX?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #781 out of 835 companies for Days Sales Outstanding. This places Regen BioPharma in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Regen BioPharma's value of 423.00 is 513.6% above this benchmark. Historically, Regen BioPharma's own Days Sales Outstanding has ranged from 146.31 to 391.18 over the past decade. While the company's 10-year median is 288.68 vs. the industry median of 68.94, Regen BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regen BioPharma's current Days Sales Outstanding of 423.00 is 513.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Days Sales Outstanding is 423.00, which is 47% above median its own 10-year median of 288.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Days Sales Outstanding is 423.00, which is 47% above median its 10-year median of 288.68 and 513.6% above the Biotechnology industry median of 68.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Days Sales Outstanding is 423.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 
